Search

Zai Lab Ltd ADR

Aperta

SettoreSettore sanitario

19.35 -5.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

18.93

Massimo

20.49

Metriche Chiave

By Trading Economics

Entrata

-607K

-51M

Vendite

-28M

100M

EPS

-0.46

Margine di Profitto

-51.215

Dipendenti

1,784

EBITDA

4.1M

-44M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+64.63% upside

Dividendi

By Acuity

Utili prossimi

6 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-67M

2.3B

Apertura precedente

24.36

Chiusura precedente

19.35

Notizie sul Sentiment di mercato

By Acuity

100%

0%

319 / 340 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 lug 2026, 23:51 UTC

News

Cavco Industries Inc. announced its first-quarter earnings release date, contributing to positive investor sentiment. Shares are higher in after-market trading.

23 lug 2026, 23:51 UTC

News

Scholastic Corp shares fell in after-market trading following fourth-quarter results, where revenue of $476.1 million missed expectations and net income dropped to $9.4 million.

23 lug 2026, 23:51 UTC

News
Social Media

Leidos Holdings shares are lower in after-market trading amid concerns over long-term revenue growth, despite a backlog of $48.37 billion.

23 lug 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

23 lug 2026, 23:51 UTC

News

PayPal shares are lower in after-market trading as Stripe and Advent assess acquisition options, with prior offers reportedly considered insufficient.

23 lug 2026, 23:46 UTC

News

Delek US Holdings Inc declared a quarterly dividend of $0.255 per share, contributing to shares trading higher in after-market hours.

23 lug 2026, 23:46 UTC

News
Social Media

CSX Corp shares rose in after-market trading following stronger-than-expected second-quarter results, with earnings of $0.54 per share and revenue of $3.94 billion.

23 lug 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

23 lug 2026, 23:41 UTC

Event
News

GE Healthcare appointed George Newcomb as interim CFO and reported $5.30 billion in second-quarter revenue, with shares higher in after-market trading.

23 lug 2026, 23:41 UTC

News

Albertsons Companies reported revenue growth in Q1 2026, despite margin contraction. Shares are modestly higher in after-market trading since Thursday's close.

23 lug 2026, 23:41 UTC

News

Charter Communications launched a private offer to exchange notes, potentially issuing up to $1.75 billion in new notes, with shares trading higher in after-market hours.

23 lug 2026, 23:31 UTC

Social Media
Correlated Moves
News

Newmont Corporation's adjusted EPS of $2.10 missed estimates, with revenue at $6.12 billion, leading to a decline in after-market trading.

23 lug 2026, 23:31 UTC

News

Appian Corp's digital application update for community services workers supports over 210,000 and processed more than $100 million, boosting shares in after-market hours.

23 lug 2026, 23:26 UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

23 lug 2026, 23:26 UTC

News

Hims & Hers Health Inc shares are higher after an FDA advisory panel recommended easing restrictions on a popular peptide and Canaccord reiterated a Buy rating.

23 lug 2026, 23:21 UTC

News

Robert Half shares are trading lower in after-market hours following a second-quarter revenue decline to $1.336 billion and a cautious outlook for Q3.

23 lug 2026, 23:21 UTC

Social Media
News

Maxlinear Inc's shares fell in after-hours trading following second-quarter results, with net revenue of $168.8 million but diluted earnings of $0.02 per share.

23 lug 2026, 23:21 UTC

News

McKesson Corp shares fell in after-market trading amid weakness in the Health Care Distributors sector, despite strong annual revenue and earnings growth.

23 lug 2026, 23:02 UTC

ETF Constituents
News

Vanguard Large-Cap ETF gains after hours, supported by major holdings like Microsoft and Tesla, despite broader market declines from new tariffs announced by President Trump.

23 lug 2026, 23:02 UTC

ETF Constituents
Social Media
News

Invesco QQQ Trust Series I rises in after-market trading, supported by positive sentiment from Intel's projected capital expenditures exceeding $20 billion.

23 lug 2026, 23:02 UTC

Social Media
News

RingCentral's revenue of $657 million surpassed estimates, prompting a raised full-year guidance. Shares are higher in after-market trading, rebounding from an earlier session low.

23 lug 2026, 23:02 UTC

Correlated Moves
News

Ovintiv Inc reported second-quarter earnings that missed expectations, with an EPS of $1.62. Shares are lower in after-market trading following the results.

23 lug 2026, 23:02 UTC

Social Media
News

Appfolio Inc shares are lower in after-market trading following second-quarter earnings. Revenue guidance of $1.117 billion to $1.127 billion fell short of expectations.

23 lug 2026, 23:02 UTC

News

Selective Insurance Group shares fell in after-hours trading following mixed second-quarter results, despite net income of $127.1 million and revenue of $1.39 billion.

23 lug 2026, 23:02 UTC

News
Social Media

Comfort Systems USA reported strong Q2 earnings and revenue, but shares are trading lower in after-market hours, indicating a shift in market sentiment.

23 lug 2026, 23:02 UTC

Social Media
News

Amkor Technology announced a $1.5 billion partnership with NVIDIA to enhance packaging capacity, boosting shares significantly in after-market hours.

23 lug 2026, 23:02 UTC

Correlated Moves
News

ServiceNow shares are higher in after-market hours as Macquarie raised its price target to $110, reflecting positive market sentiment and sector dynamics.

23 lug 2026, 23:02 UTC

Social Media
News

Intel Corp reported second-quarter revenue of $16.1 billion, exceeding expectations. The positive outlook has driven shares higher in after-market hours.

23 lug 2026, 23:02 UTC

News

Boeing Co shares are lower in after-market trading after announcing the divestiture of its stake in HRL Laboratories, LLC, amid broader market pressures.

23 lug 2026, 23:01 UTC

News
Social Media
Event

Tenet Healthcare Corp reported second-quarter adjusted EPS of $6.12, exceeding estimates. Shares are trading higher in after-market hours following strong earnings and raised guidance.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

64.63% in crescita

Previsioni per 12 mesi

Media 32.4 USD  64.63%

Alto 44 USD

Basso 21.6 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

319 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat